Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 11 min ago
Peer-reviewedCC BY 4.0The Breast Journal

Burden and Projections of Premenopausal and Postmenopausal Breast Cancer Worldwide: A Comprehensive Analysis of GLOBOCAN 2022 Data

  • Rongbo Ding1
  • Hongyan Jia2
  1. 1Department of Breast Surgery Heping Hospital Affiliated to Changzhi Medical College Changzhi Shanxi China
  2. 2Department of Breast Surgery First Hospital of Shanxi Medical University Taiyuan Shanxi China sxmu.edu.cn
Read full textPDFDOICite

Abstract

Objectives: Breast cancer is the most diagnosed cancer among women worldwide, yet important epidemiological differences exist between premenopausal and postmenopausal disease. Updated global estimates stratified by menopausal status are limited. This study aimed to quantify the global, regional, and national burden of premenopausal and postmenopausal breast cancer in 2022 and to project future trends through 2050.

Methods: Breast cancer incidence and mortality data for 2022 were obtained from the International Agency for Research on Cancer GLOBOCAN database. Women aged 15–49 years were classified as premenopausal and those aged ≥ 50 years as postmenopausal. Age‐standardized incidence rates (ASIRs), age‐standardized mortality rates (ASMRs), cumulative risk, and mortality‐to‐incidence ratios (MIRs) were estimated for 185 countries. Countries were further stratified by the Human Development Index (HDI) published by the United Nations Development Programme. Temporal trends were assessed using estimated annual percentage change (EAPC), and projections to 2050 were derived using the World Health Organization Cancer Tomorrow tool.

Results: In 2022, an estimated 2,296,607 new breast cancer cases and 666,061 deaths occurred globally. Premenopausal women accounted for 668,417 cases (29.1%) and 141,338 deaths (21.2%), while postmenopausal women accounted for 1,628,190 cases (70.9%) and 524,723 deaths (78.8%). Global ASIRs were 32.7 and 153.9 per 100,000 for premenopausal and postmenopausal women, respectively. Incidence rates were highest in very high‐HDI countries, whereas mortality and MIR were markedly higher in low‐HDI countries. Africa showed the highest MIRs for both premenopausal (40.3%) and postmenopausal (51.8%) breast cancer. HDI was positively correlated with cumulative incidence risk but strongly inversely correlated with MIR. By 2050, global cases are projected to increase to 795,908 for premenopausal and 2,756,889 for postmenopausal breast cancer.

Conclusions: Substantial global disparities exist in breast cancer burden and outcomes. While high‐income countries experience higher incidence, low‐resource settings bear disproportionately higher mortality. Strengthening early detection, treatment access, and cancer control systems is essential to reduce global inequities and address the growing burden of breast cancer.

Related

  1. Association of Circulating Irisin with Adiposity, Sarcopenia-Related Indices, and Phenotypes in Premenopausal and Postmenopausal Women
    Nouf Aljawini, Syed Shahid Habib, Khalid Al-Regaiey
    NutrientsPeer-reviewedCC BY 4.0Epidemiology & public healthCrossref
  2. Burden, trends, and projections of prostate cancer: global cancer statistics (GLOBOCAN) estimates for 2024 and 2022
    Xiaomin Liu, Wenlong Zheng, Yuting Ji +6
    Journal of the National Cancer CenterPeer-reviewedCC BY-NC-ND 4.0Full textOncologyPMC
  3. Global and registry-based patterns of pancreatic cancer: GLOBOCAN 2020, CI5plus trends (2000–2017), and demographic projections to 2040
    Xin Jin, Xiao Guan, Yongrun Mu +2
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyPMCCrossrefEurope PMC
  4. Global burden, geographic and sex disparities, and projections to 2050 for salivary gland cancer across G20 countries: a GLOBOCAN 2024 analysis
    Wen Yang, Yuzhen Ma, Chunxia Shu
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefDOAJ
  5. Nasopharyngeal carcinoma burden in the United States and worldwide, 1990 to 2023: A pairwise analysis with mortality projections to 2050.
    Ibraheem Altamimi, Zainab Yunus Alfallatah, Abdulrahman Alzmmam +10
    MedicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{ding2026burden,
  title = {{Burden and Projections of Premenopausal and Postmenopausal Breast Cancer Worldwide: A Comprehensive Analysis of GLOBOCAN 2022 Data}},
  author = {Rongbo Ding and Hongyan Jia},
  journal = {The Breast Journal},
  year = {2026},
  month = nov,
  doi = {10.1155/tbj/1290471},
  url = {https://doi.org/10.1155/tbj/1290471},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Burden and Projections of Premenopausal and Postmenopausal Breast Cancer Worldwide: A Comprehensive Analysis of GLOBOCAN 2022 Data
AU  - Rongbo Ding
AU  - Hongyan Jia
PY  - 2026
DA  - 2026/11/04
JO  - The Breast Journal
DO  - 10.1155/tbj/1290471
UR  - https://doi.org/10.1155/tbj/1290471
AB  - Objectives: Breast cancer is the most diagnosed cancer among women worldwide, yet important epidemiological differences exist between premenopausal and postmenopausal disease. Updated global estimates stratified by menopausal status are limited. This study aimed to quantify the global, regional, and national burden of premenopausal and postmenopausal breast cancer in 2022 and to project future trends through 2050.  Methods: Breast cancer incidence and mortality data for 2022 were obtained from the International Agency for Research on Cancer GLOBOCAN database. Women aged 15–49 years were classified as premenopausal and those aged ≥ 50 years as postmenopausal. Age‐standardized incidence rates (ASIRs), age‐standardized mortality rates (ASMRs), cumulative risk, and mortality‐to‐incidence ratios (MIRs) were estimated for 185 countries. Countries were further stratified by the Human Development Index (HDI) published by the United Nations Development Programme. Temporal trends were assessed using estimated annual percentage change (EAPC), and projections to 2050 were derived using the World Health Organization Cancer Tomorrow tool.  Results: In 2022, an estimated 2,296,607 new breast cancer cases and 666,061 deaths occurred globally. Premenopausal women accounted for 668,417 cases (29.1%) and 141,338 deaths (21.2%), while postmenopausal women accounted for 1,628,190 cases (70.9%) and 524,723 deaths (78.8%). Global ASIRs were 32.7 and 153.9 per 100,000 for premenopausal and postmenopausal women, respectively. Incidence rates were highest in very high‐HDI countries, whereas mortality and MIR were markedly higher in low‐HDI countries. Africa showed the highest MIRs for both premenopausal (40.3%) and postmenopausal (51.8%) breast cancer. HDI was positively correlated with cumulative incidence risk but strongly inversely correlated with MIR. By 2050, global cases are projected to increase to 795,908 for premenopausal and 2,756,889 for postmenopausal breast cancer.  Conclusions: Substantial global disparities exist in breast cancer burden and outcomes. While high‐income countries experience higher incidence, low‐resource settings bear disproportionately higher mortality. Strengthening early detection, treatment access, and cancer control systems is essential to reduce global inequities and address the growing burden of breast cancer.
SN  - 1075-122X
SN  - 1524-4741
ER  -